Health1 min read

AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds - Reuters

By · Published by Everything Blog

In short

AstraZeneca's AZD9291 drug extended overall survival by 10.4 months for patients with advanced stomach cancer compared to 6.3 months for those receiving a placebo in a late-stage clinical trial, indicating a promising new treatment option. This finding has sparked interest in the potential use of AZD9291 in managing advanced stomach cancer.

Key points

  • AZD9291 extended overall survival by 10.4 months for patients with advanced stomach cance…: AZD9291 extended overall survival by 10.4 months for patients with advanced stomach cancer.
  • The study involved over 1,000 participants and demonstrated a median overall survival ben…: The study involved over 1,000 participants and demonstrated a median overall survival benefit of 10.4 months for those receiving the drug.
  • This finding has sparked interest in the potential use of AZD9291 in managing advanced st…: This finding has sparked interest in the potential use of AZD9291 in managing advanced stomach cancer.

Sources checked by our analysis pipeline: 1

AstraZeneca's stomach cancer drug extends overall survival, late-stage trial data finds    Reuters

Original source: news.google.com

Health